Bernadette Connaughton
Director/Board Member bij HALOZYME THERAPEUTICS, INC.
Vermogen: 3 M $ op 31-03-2024
Actieve functies van Bernadette Connaughton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director/Board Member | 10-09-2018 | - |
| Independent Dir/Board Member | 10-09-2018 | - | |
| ZEALAND PHARMA A/S | Director/Board Member | 04-04-2019 | - |
| Independent Dir/Board Member | 04-04-2019 | - | |
| EDITAS MEDICINE, INC. | Director/Board Member | 26-10-2021 | - |
| Independent Dir/Board Member | 26-10-2021 | - | |
| Boys & Girls Clubs of New Jersey | Director/Board Member | - | - |
Loopbaan van Bernadette Connaughton
Eerdere bekende functies van Bernadette Connaughton
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SYNEOS HEALTH, INC. | Director/Board Member | 12-11-2019 | 28-09-2023 |
| Independent Dir/Board Member | 12-11-2019 | 28-09-2023 | |
| VISTERRA INC | Director/Board Member | 01-12-2015 | 01-08-2018 |
| Bristol-Myers Squibb Pharma Co. | Corporate Officer/Principal | 01-01-2004 | 01-10-2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2004 | 01-01-2017 |
Opleiding van Bernadette Connaughton
| The Johns Hopkins University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 10 |
| Denemarken | 2 |
Operationeel
| Director/Board Member | 6 |
| Independent Dir/Board Member | 4 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 7 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
| Bristol-Myers Squibb Pharma Co. | |
| Boys & Girls Clubs of New Jersey | |
Syneos Health, Inc.
 Syneos Health, Inc. BiotechnologyHealth Technology Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
